Biotech

Latest Articles

Basilea scores $268M BARDA financing for antifungals, antibiotics

.Basilea Pharmaceutica's work establishing brand new antifungals has actually obtained a notable imp...

Capricor sells Europe rights to late-stage DMD treatment for $35M

.Having presently scooped up the USA civil liberties to Capricor Therapeutics' late-stage Duchenne m...

FDA fragments adcomm for Applied's rare condition medication

.After pushing the choice meeting for Applied Therapeutics' metabolic disorder drug govorestat, the ...

Novo inks $600M NanoVation package to examine genetic medications ex-liver

.Novo Nordisk is continuing its own push in to hereditary medications, accepting pay NanoVation Ther...

Innovent web links cytokine to intestines cancer actions

.Innovent Biologics has actually made the instance that its own gate inhibitor-cytokine blend protei...

Merck, Daiichi ADC hits target in stage 3 lung cancer research study

.A period 3 test of Daiichi Sankyo and also Merck &amp Co.'s HER3-directed antibody-drug conjugate (...

Rakovina grows artificial intelligence focus with collab to pick cancer cells targets

.Five months after Rakovina Rehabs pivoted towards artificial intelligence, the cancer-focused biote...

Ascendis' dwarfism drug smash hits in phase 3, threatens BioMarin

.Ascendis Pharma has emerged as a potential danger to BioMarin's Voxzogo, reporting stage 3 growth d...

Despite ph. 3 overlook, Alkeus observes path ahead of time for eye disease asset

.Though Alkeus Pharmaceuticals' oral eye disease resource neglected to dramatically lessen geographi...

Kairos goes public along with $6M IPO to cash trials of cancer medicine

.With a trio of biotechs reaching the Nasdaq on Friday, it was actually very easy to overlook a smal...

Vaccine and also Keytruda combination helpful in squamous tissue carcinoma

.Immune system checkpoint inhibitors are the superheroes of cancer cells therapy. Medications like B...

Cue Biopharma mark time J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, firings a...

Regeneron's Opdualag rival reveals 57% feedback rate

.Regeneron is actually back with long-lasting follow-up for its own LAG-3 prevention and PD-1 preven...

AstraZeneca articles information on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early consider the functionality of its own in-house anti...

iTeos- GSK's TIGIT celebrity shows purposeful renovation

.After announcing a period 3 launch based on positive midstage end results, iTeos and GSK are ultima...

More collective FDA can easily accelerate rare health condition R&ampD: report

.The FDA needs to be actually extra open and also collective to release a surge in approvals of rare...

Zenas, MBX, Bicara scalp to Nasdaq in scorching day for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Reh...

Atea's COVID antiviral fails to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has fallen short one more COVID-19 trial, but the biotech still sto...

Neurocrine's quote to save schizophrenia possibility falls short

.Neurocrine Biosciences' mental illness plan pivot has actually failed. The biotech was not able to ...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has brought in an overdue access to the radioligand party, paying for 100 thousand europeans...